9.41 USD
▼-0.50-5.09%
盘后 10.27 0.00%
2026-11-20
市值
$271.32M
市盈率
—
EPS
-1.86
股息率
—
52 周区间
7.88 – 17.80
成交量
9.48K
Beta
0.10
目标价
24.41
52W 低 7.8852W 高 17.80
价格走势
公司简介
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III cl...